Retinoic Acid Receptor Agonists Drug Pipeline Research Report 2022 –

Retinoic Acid Receptor Agonists Drug Pipeline Research Report 2022 –

Retinoic Acid Receptor Agonists Drug Pipeline Research Report 2022 –

DUBLIN–(BUSINESS WIRE)–The “Retinoic acid receptor agonists – Pipeline Insight, 2022” drug pipelines has been added to’s offering.

The report serves as an exhaustive source of insights into the landscape of Retinoic Acid Receptor (RARs) Agonist pipeline, encompassing over 15 companies and 15 pipeline drugs.

It presents detailed profiles of these pipeline drugs, spanning both clinical and nonclinical stages. The report provides a comprehensive evaluation of these therapeutic candidates based on factors such as product type, development stage, administration route, and molecule type. Additionally, it sheds light on the presence of inactive pipeline products within this domain.

Within the realm of Retinoic Acid Receptor (RARs) Agonist, the collaborative efforts of companies and researchers are directed towards understanding challenges and seizing opportunities that could shape the trajectory of R&D activities. The ongoing development of therapies revolves around innovative strategies, aiming to address the intricacies of Retinoic Acid Receptor (RARs) Agonist.

Retinoic Acid Receptor (RARs) Agonist Emerging Drugs Chapters

This segment of the Retinoic Acid Receptor (RARs) Agonist report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Retinoic Acid Receptor (RARs) Agonist Emerging Drugs

Palovarotene: Clementia Pharmaceuticals (Ipsen)

Palovarotene is a RAR-y agonist being developed as a potential treatment for patients with ultra-rare and debilitating bone diseases, including fibrodysplasia ossificans progressiva (FOP) and multiple osteochondromas (MO), as well as other conditions including dry eye disease. Palovarotene had received rare pediatric disease and breakthrough therapy designations for the treatment of an ultra-rare bone disorder.

IRX 5183: Allergan (AbbVie)

IRX 5183 is a selective, orally available, third generation vitamin A derivative and first in class Retinoic Acid Receptor alpha (RAR?) agonist. IRX 5183 is a drug that is designed to cause cancer cells to mature and then die. The drug is in Phase I/II clinical development for the treatment of cancer.

Retinoic Acid Receptor (RARs) Agonist: Therapeutic Assessment

This segment of the report provides insights about the different Retinoic Acid Receptor (RARs) Agonist drugs segregated based on following parameters that define the scope of the report.

Major Players working on Retinoic Acid Receptor (RARs) Agonist

There are approx. 15+ key companies which are developing the Retinoic Acid Receptor (RARs) Agonist. The companies which have their Retinoic Acid Receptor (RARs) Agonist drug candidates in the most advanced stage, i.e. Phase III include, Clementia Pharmaceuticals (Ipsen).

Retinoic Acid Receptor (RARs) Agonist: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Retinoic Acid Receptor (RARs) Agonist therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Retinoic Acid Receptor (RARs) Agonist drugs.

Current Scenario and Emerging Therapies:

  • How many companies are developing Retinoic Acid Receptor (RARs) Agonist drugs?
  • How many Retinoic Acid Receptor (RARs) Agonist drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for Retinoic Acid Receptor (RARs) Agonist?
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Retinoic Acid Receptor (RARs) Agonist therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Retinoic Acid Receptor (RARs) Agonist and their status?
  • What are the key designations that have been granted to the emerging drugs?


This report covers around 15+ products under different phases of clinical development like

  • Late-stage products (Phase III and
  • Mid-stage products (Phase II and
  • Early-stage products (Phase I/II and Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration

Products have been categorized under various ROAs such as

  • Infusion
  • Intradermal
  • Intramuscular
  • Intranasal
  • Intravaginal
  • Oral
  • Parenteral
  • Subcutaneous
  • Topical
  • Molecule Type

Products have been categorized under various Molecule types such as

  • Vaccines
  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Product Type

Retinoic Acid Receptor (RARs) Agonist Report Insights

  • Retinoic Acid Receptor (RARs) Agonist Pipeline Analysis
  • Therapeutic Assessment
  • Unmet Needs
  • Impact of Drugs

Retinoic Acid Receptor (RARs) Agonist Report Assessment

  • Pipeline Product Profiles
  • Therapeutic Assessment
  • Pipeline Assessment
  • Inactive drugs assessment
  • Unmet Needs

Key Players

  • Clementia Pharmaceuticals (Ipsen)
  • Nippon Shinyaku
  • Bausch Health Companies
  • Galderma
  • Avecho Biotechnology
  • Allergan (AbbVie)
  • Celgene
  • SciTech Development
  • Polaryx Therapeutics

Key Products

  • Palovarotene
  • Tamibarotene
  • IDP 126
  • CD-5789
  • Tretinoin topical
  • IRX 5183
  • Cintirorgon
  • Fenretinide intravenous
  • PLX-200

For more information about this drug pipelines report visit

About is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.


Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470

For U.S./ CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900